James A. Boiani, a Member of the Firm, and John S. Linehan, an Associate, in the Health Care and Life Sciences practice, in the firm's Washington, DC, office, authored an article in Law360, titled “FDA Signals Tougher Approach to Animal Drug Compounding.” (Read the full version — subscription required.)

Following is an excerpt:

On May 18, 2015, the U.S. Food and Drug Administration withdrew its 2003 Compliance Policy Guide — Section 608.400, Compounding of Drugs for Use in Animals and signaled new plans to constrain animal drug compounding in its Draft Guidance for Industry (GFI) #230, Compounding Animal Drugs from Bulk Drug Substances. The draft guidance suggests that a dramatic shift in the FDA’s enforcement approach may be underway and provides insight into the FDA’s enforcement priorities and its interpretation of the applicable regulatory regime. Stakeholders have until Aug. 17, 2015, to submit comments that could influence the final guidance and policies adopted by the agency.

The draft guidance states that, like human drug compounding, the FDA aims to ensure that state-regulated traditional compounding of animal drugs is permitted only in response to prescriptions for individually identified patients. This conflicts with laws in several states that currently authorize the practice of “office use” compounding, in which animal drugs are compounded in advance of receiving patient-specific prescriptions. In addition, the FDA encourages sterile animal drug compounders to register as “outsourcing facilities” — a category of federally regulated entities that was established through enactment of the Drug Quality and Security Act of 2013 and has been utilized for human drug compounding facilities.

This article is based on an Epstein Becker Green Health Care and Life Sciences Client Alert, “FDA Signals Restrictive Regulatory Approach in Draft Guidance on Animal Drug Compounding,” authored by Mr. Boiani and Mr. Linehan.

Jump to Page

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.